Harry D Bear, MD

Unless otherwise indicated, this information has been self-reported and has not been verified by the Board of Medicine.

Virginia Commonwealth University School Of Medicine (Previously MCV) - Richmond VA
Rank: Full Professor
Years: 1984-Present

None Reported

Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27
Journal of Clinical Oncology
Volume: 24
Date: 05 2006

The effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
J.Clin.Oncol.
Volume: 16
Date: 08 2006

Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.
Journal of Clinical Oncology
Volume: 26
Date: 02 2008

Neoadjuvant Chemotherapy for Operable Breast Cancer: Individualizing Loco-Regional and Systemic Therapy,
Surgical Oncology Clinics of North America
Volume: 19
Date: 07 2010

Bevacizumab added to neoadjuvant chemotherapy for breast cancer.
New England Journal of Medicine
Volume: 366
Date: 01 2012

Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
Lancet Oncology
Volume: 14
Date: 11 2013

Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial.
Lancet Oncology
Volume: 16
Date: 09 2016

If we build it they will come: targeting the immune response to breast cancer
NPJ Breast Cancer
Date: 10 2019

Long Term Primary Results of Partial Breast Irradiation after Breast Conserving Surgery for Early Stage Breast Cancer.
The Lancet
Volume: 394
Date: 12 2019

The DNA methyltransferase inhibitor, guadecitabine, targets tumor-induced myelopoiesis and recovers T cell activity to slow tumor growth in combination with adoptive immunotherapy in a mouse model of breast cancer.
BMC Immunology
Date: 02 2020